IN189722B - - Google Patents

Info

Publication number
IN189722B
IN189722B IN1694DE1998A IN189722B IN 189722 B IN189722 B IN 189722B IN 1694DE1998 A IN1694DE1998 A IN 1694DE1998A IN 189722 B IN189722 B IN 189722B
Authority
IN
India
Application number
Other languages
English (en)
Inventor
Stephen Alistair Smith
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26311745&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN189722(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9712857.3A external-priority patent/GB9712857D0/en
Priority claimed from GBGB9806706.9A external-priority patent/GB9806706D0/en
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of IN189722B publication Critical patent/IN189722B/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/155Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
IN1694DE1998 1997-06-18 1998-06-18 IN189722B (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9712857.3A GB9712857D0 (en) 1997-06-18 1997-06-18 Novel method of treatment
GBGB9806706.9A GB9806706D0 (en) 1998-03-27 1998-03-27 Novel method

Publications (1)

Publication Number Publication Date
IN189722B true IN189722B (fr) 2003-04-19

Family

ID=26311745

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1694DE1998 IN189722B (fr) 1997-06-18 1998-06-18

Country Status (39)

Country Link
US (3) US20060100247A1 (fr)
EP (2) EP1787646A3 (fr)
JP (1) JP2002504137A (fr)
KR (2) KR20060105005A (fr)
CN (2) CN1230171C (fr)
AP (1) AP1279A (fr)
AR (2) AR012995A1 (fr)
AT (1) ATE355840T1 (fr)
AU (1) AU8539398A (fr)
BG (2) BG64818B1 (fr)
BR (1) BR9810172A (fr)
CA (1) CA2294582C (fr)
CY (2) CY1107643T1 (fr)
CZ (1) CZ298469B6 (fr)
DE (2) DE122007000054I1 (fr)
DK (1) DK0996444T3 (fr)
DZ (1) DZ2520A1 (fr)
EA (1) EA003144B1 (fr)
ES (1) ES2284212T3 (fr)
HK (1) HK1028193A1 (fr)
ID (1) ID23372A (fr)
IL (3) IL133142A0 (fr)
IN (1) IN189722B (fr)
LU (1) LU91356I2 (fr)
MA (1) MA26512A1 (fr)
MY (1) MY129897A (fr)
NL (1) NL300288I2 (fr)
NO (4) NO324993B1 (fr)
NZ (1) NZ501260A (fr)
OA (1) OA11516A (fr)
PE (1) PE83199A1 (fr)
PL (2) PL195140B1 (fr)
PT (1) PT996444E (fr)
SI (1) SI0996444T1 (fr)
SK (1) SK286029B6 (fr)
TR (1) TR199903057T2 (fr)
TW (1) TW565449B (fr)
UY (1) UY25049A1 (fr)
WO (1) WO1998057634A1 (fr)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5798375A (en) * 1995-07-03 1998-08-25 Sankyo Company, Limited Treatment of arteriosclerosis and xanthoma
GB9712857D0 (en) * 1997-06-18 1997-08-20 Smithkline Beecham Plc Novel method of treatment
DE69818444T2 (de) * 1998-07-15 2004-05-06 Merck Santé Tabletten enthaltend eine Kombination von Glibenclamid und Metformin
WO2000053171A1 (fr) * 1999-03-05 2000-09-14 Molteni L. E C. Dei Fratelli Alitti Societa' Di Esercizio S.P.A. Utilisation de metformine dans la preparation de compositions pharmaceutiques pouvant inhiber l'enzyme dipeptidyl peptidase iv
TWI249401B (en) 1999-04-14 2006-02-21 Takeda Chemical Industries Ltd Agent for improving ketosis
OA11871A (en) 1999-04-23 2006-03-27 Smithkline Beecham Plc Novel pharmaceutical.
BR0015294A (pt) 1999-11-03 2003-07-15 Bristol Myers Squibb Co Método para tratamento da diabetes
US6586438B2 (en) * 1999-11-03 2003-07-01 Bristol-Myers Squibb Co. Antidiabetic formulation and method
MY125516A (en) * 1999-11-16 2006-08-30 Smithkline Beecham Plc Novel composition based on thiazolidinedione and metformin and use
JP2003514011A (ja) * 1999-11-16 2003-04-15 スミスクライン ビーチャム パブリック リミテッド カンパニー チアゾリジンジオン−塩酸メトホルミンを含む医薬組成物
US20010036479A1 (en) 2000-01-14 2001-11-01 Gillian Cave Glyburide composition
GB0006133D0 (en) 2000-03-14 2000-05-03 Smithkline Beecham Plc Novel pharmaceutical
EP1278513B1 (fr) * 2000-05-01 2007-07-18 Aeropharm Technology, LLC Formulation de noyaux
FR2812547B1 (fr) * 2000-08-04 2002-10-31 Lipha Composition pharmaceutique comprenant une association metformine et derive de thiazolidinedione et son utilisation pour la preparation de medicaments destines a traiter le diabete
WO2002055009A1 (fr) 2001-01-12 2002-07-18 Sun Pharmaceutical Industries Limited Systeme de liberation espacee de medicaments
FR2838968A1 (fr) * 2002-04-30 2003-10-31 Lipha Association d'insuline et d'un derive de thiazolidinedione et son utilisation pour traiter le diabete
KR100897890B1 (ko) 2002-06-17 2009-05-18 인벤티아 헬스케어 피브이티. 엘티디. 티아졸리딘디온 및 바이구아나이드를 함유하는 다층 정제및 그의 제조 방법
KR20100137023A (ko) * 2002-09-20 2010-12-29 안드렉스 랩스 엘엘씨 약제학적 정제
UA80991C2 (en) * 2002-10-07 2007-11-26 Solid preparation containing an insulin resistance improving drug and an active ingredient useful as a remedy for diabetes
BRPI0407074A (pt) 2003-01-29 2006-01-24 Takeda Pharmaceutical Método para produção de uma preparação revestida, preparação revestida, e, método para melhorar a dissolução do cloridreto de pioglitazona de uma preparação revestida com cloridreto de pioglitazona
EP1738754B1 (fr) 2004-04-14 2015-07-15 Takeda Pharmaceutical Company Limited Preparation pharmaceutique solide
CN1327840C (zh) * 2004-06-08 2007-07-25 天津药物研究院 一种药物组合物及其在制备用于治疗糖尿病中的应用
WO2006011397A1 (fr) * 2004-07-27 2006-02-02 Kowa Company., Ltd. Médicament pour la prévention ou le traitement du diabète
US20070032420A1 (en) * 2005-02-09 2007-02-08 Entelos, Inc. Treating diabetes with glucagon-like peptide-1 secretagogues
CN101272805A (zh) * 2005-07-12 2008-09-24 第一三共株式会社 包含PPARγ激动剂的药物组合物
US7435741B2 (en) 2006-05-09 2008-10-14 Teva Pharmaceutical Industries, Ltd. 2-N{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2,4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate
EP1854794A1 (fr) * 2006-05-09 2007-11-14 Teva Pharmaceutical Industries Ltd. Acide 2-N-{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2-4-thiazolidinedione} butanedioique, procédés de préparation et compositions avec le maléate de rosiglitazone
CN101069745B (zh) * 2006-05-12 2010-07-21 北京华安佛医药研究中心有限公司 治疗2型糖尿病的药物组合物
US7919410B2 (en) * 2007-03-14 2011-04-05 Aptina Imaging Corporation Packaging methods for imager devices
CN105152919A (zh) * 2008-07-28 2015-12-16 赛丹思科大学 用于治疗代谢疾病的化合物
DE102009053562A1 (de) 2009-11-18 2011-05-19 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Rosiglitazonsuccinat enthaltende pharmazeutische Zusammensetzung
US9211263B2 (en) 2012-01-06 2015-12-15 Elcelyx Therapeutics, Inc. Compositions and methods of treating metabolic disorders
US9572784B2 (en) 2011-01-07 2017-02-21 Elcelyx Therapeutics, Inc. Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
SG10201607085WA (en) 2011-01-07 2016-10-28 Elcelyx Therapeutics Inc Chemosensory Receptor Ligand-Based Therapies
US11974971B2 (en) 2011-01-07 2024-05-07 Anji Pharmaceuticals Inc. Compositions and methods for treating metabolic disorders
US11759441B2 (en) 2011-01-07 2023-09-19 Anji Pharmaceuticals Inc. Biguanide compositions and methods of treating metabolic disorders
US9480663B2 (en) 2011-01-07 2016-11-01 Elcelyx Therapeutics, Inc. Biguanide compositions and methods of treating metabolic disorders
US8796338B2 (en) 2011-01-07 2014-08-05 Elcelyx Therapeutics, Inc Biguanide compositions and methods of treating metabolic disorders
JP6175074B2 (ja) 2012-01-06 2017-08-02 エルセリクス セラピューティクス インコーポレイテッド 代謝障害を治療するための組成物および方法
BR112014016808B1 (pt) 2012-01-06 2022-01-11 Anji Pharma (Us) Llc Uso de um composto de biguanida para a fabricação de um medicamento para baixar os níveis de glicose no sangue e para o tratamento de um distúrbio do metabolismo de glicose

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5522636A (en) * 1978-08-04 1980-02-18 Takeda Chem Ind Ltd Thiazoliding derivative
JPS5697277A (en) * 1980-01-07 1981-08-05 Takeda Chem Ind Ltd Thiazolidine derivative
JPS6051189A (ja) * 1983-08-30 1985-03-22 Sankyo Co Ltd チアゾリジン誘導体およびその製造法
CN1003445B (zh) * 1984-10-03 1989-03-01 武田药品工业株式会社 噻唑烷二酮衍生物,其制备方法和用途
JPH06779B2 (ja) * 1985-06-10 1994-01-05 武田薬品工業株式会社 チアゾリジオン誘導体およびそれを含んでなる医薬組成物
US4812570A (en) * 1986-07-24 1989-03-14 Takeda Chemical Industries, Ltd. Method for producing thiazolidinedione derivatives
EP0842925A1 (fr) * 1987-09-04 1998-05-20 Beecham Group Plc Thiazolidinédiones substituées
US4895862A (en) * 1989-04-21 1990-01-23 American Home Products Corp. Novel benzyl-3H-1,2,3,5-oxathiadiazole 2-oxides useful as antihyperglycemic agents
US5068342A (en) * 1989-10-27 1991-11-26 American Home Products Corporation 5-[(1- and 2-naphthalenyl)thio and sulfonyl]-2,4-thiazolidinediones and derivatives thereof
WO1991007107A1 (fr) * 1989-11-13 1991-05-30 Pfizer Inc. Agents d'oxazolidinedione hypoglycemiques
JPH04210683A (ja) * 1990-12-06 1992-07-31 Terumo Corp チアゾリジン−2,4−ジオン誘導体およびこれを含有する糖尿病合併症治療薬
EP0601001B1 (fr) * 1991-08-26 1997-04-16 PHARMACIA & UPJOHN COMPANY Composition alimentaire liquide contenant de l'acide 3-guanidinopropionique
GB9218830D0 (en) * 1992-09-05 1992-10-21 Smithkline Beecham Plc Novel compounds
MX9709874A (es) * 1995-06-06 1998-03-31 Pfizer N-(INDOL-2-CARBONIL) beta-ALANILAMIDAS SUSTITUIDAS Y DERIVADOS COMO INHIBIDORES DE GLUCOGENO FOSFORILASA, USO DE LOS MISMOS Y COMPOSICIONES QUE LOS CONTIENEN.
TW438587B (en) * 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
JPH09270635A (ja) * 1996-04-01 1997-10-14 Honda Motor Co Ltd 平面アンテナモジュール
US5859037A (en) * 1997-02-19 1999-01-12 Warner-Lambert Company Sulfonylurea-glitazone combinations for diabetes
US6153632A (en) * 1997-02-24 2000-11-28 Rieveley; Robert B. Method and composition for the treatment of diabetes
US6291495B1 (en) * 1997-02-24 2001-09-18 Robert B. Rieveley Method and composition for the treatment of diabetes
US20020177612A1 (en) * 1997-06-05 2002-11-28 Smithkline Beecham P.I.C. Composition comprising 5-[4-[2-(N-methyl-N-2-pyridy)amino)ethoxy]benzyl]thiazolidine-2,4-dione
US20020016287A1 (en) * 1997-07-18 2002-02-07 Smithkline Beecham P.L.C. Treatment of diabetes with thiazolidinedione, insulin secretagogue and diguanide
JP4278863B2 (ja) * 1997-12-08 2009-06-17 ブリストル−マイヤーズ スクイブ カンパニー メトホルミンの新規塩および方法
EP1555845A1 (fr) * 2004-01-15 2005-07-20 Siemens Aktiengesellschaft Procédé de localisation des postes d'abonnés d'un système de communication radio

Also Published As

Publication number Publication date
AP1279A (en) 2004-05-20
ATE355840T1 (de) 2007-03-15
AP9901719A0 (en) 1999-12-31
DE122007000054I1 (de) 2007-12-13
IL133142A0 (en) 2001-03-19
CN1429551A (zh) 2003-07-16
ID23372A (id) 2000-04-20
CY1107643T1 (el) 2012-01-25
IL173650A0 (en) 2006-07-05
US20060100247A1 (en) 2006-05-11
CZ298469B6 (cs) 2007-10-10
PT996444E (pt) 2007-06-08
AR012995A1 (es) 2000-11-22
EP1787646A3 (fr) 2007-10-03
HK1028193A1 (en) 2001-02-09
NO2008003I2 (no) 2010-06-28
CA2294582A1 (fr) 1998-12-23
KR100666591B1 (ko) 2007-01-11
NO20063000L (no) 1999-12-17
AU8539398A (en) 1999-01-04
PL337362A1 (en) 2000-08-14
NO326958B1 (no) 2009-03-23
US20070004780A1 (en) 2007-01-04
LU91356I2 (fr) 2008-01-29
EP1787646A2 (fr) 2007-05-23
PE83199A1 (es) 1999-10-22
KR20060105005A (ko) 2006-10-09
MY129897A (en) 2007-05-31
PL195140B1 (pl) 2007-08-31
US20080090881A1 (en) 2008-04-17
DE69837261T2 (de) 2007-11-08
EP0996444B1 (fr) 2007-03-07
UY25049A1 (es) 2000-09-29
PL195136B1 (pl) 2007-08-31
EA003144B1 (ru) 2003-02-27
TR199903057T2 (xx) 2000-04-21
DK0996444T3 (da) 2007-07-02
NO996266L (no) 1999-12-17
NL300288I1 (nl) 2007-11-01
SK179299A3 (en) 2000-11-07
CN1230171C (zh) 2005-12-07
NL300288I2 (nl) 2009-06-02
NO20090846L (no) 1999-12-17
CN1114404C (zh) 2003-07-16
BG104060A (en) 2000-10-31
CN1260716A (zh) 2000-07-19
EA200000041A1 (ru) 2000-08-28
IL133142A (en) 2006-06-11
DZ2520A1 (fr) 2003-02-01
CZ9904578A3 (en) 2001-06-13
BR9810172A (pt) 2000-08-08
TW565449B (en) 2003-12-11
NZ501260A (en) 2002-09-27
MA26512A1 (fr) 2004-12-20
NO996266D0 (no) 1999-12-17
JP2002504137A (ja) 2002-02-05
OA11516A (en) 2004-02-04
WO1998057634A1 (fr) 1998-12-23
NO2008003I1 (no) 2008-04-21
CY2007018I1 (el) 2012-01-25
EP0996444A1 (fr) 2000-05-03
BG109398A (bg) 2006-05-31
DE69837261D1 (de) 2007-04-19
SI0996444T1 (sl) 2007-08-31
ES2284212T3 (es) 2007-11-01
SK286029B6 (sk) 2008-01-07
NO324993B1 (no) 2008-01-14
AR012998A1 (es) 2000-11-22
BG64818B1 (bg) 2006-05-31
CA2294582C (fr) 2008-02-12
KR20010013844A (ko) 2001-02-26

Similar Documents

Publication Publication Date Title
BE2018C032I2 (fr)
IN189722B (fr)
CH0944937H2 (fr)
ITMI971273A0 (fr)
GB9711447D0 (fr)
ITUD970098A0 (fr)
IN189879B (fr)
BE2013C047I2 (fr)
BR9701757A (fr)
BR9700653A (fr)
ITMI970993A0 (fr)
IN183682B (fr)
IN185743B (fr)
ITMI971366A0 (fr)
ITMI971551A0 (fr)
IN186198B (fr)
IN186499B (fr)
ITMI971553A0 (fr)
ITAR970020A0 (fr)
ITCA970017A0 (fr)
ITTO970397A0 (fr)
BY4238C1 (fr)
CN3058923S (fr)
CN3056826S (fr)
CN3054556S (fr)